Premium
Decision Analysis: Treatment of Pneumocystis carinii Pneumonia in Patients With AIDS
Author(s) -
Jankiewicz Ann M.
Publication year - 1992
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1992.tb03623.x
Subject(s) - pneumocystis carinii , pneumonia , trimethoprim , medicine , pentamidine , intensive care medicine , sulfamethoxazole , adverse effect , drug , human immunodeficiency virus (hiv) , immunology , antibiotics , pneumocystis jirovecii , pharmacology , biology , microbiology and biotechnology
Controversy exists as to the most appropriate drug for the initial treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Decision analysis can be used to evaluate the choice between parenteral pentamidine and trimethoprim‐sulfamethoxazole. Sensitivity and threshold analyses illustrate how the choice is affected by the probabilities of success and adverse reactions, as well as by the values placed by the patient and practitioner on treatment outcomes. A test that predicts trimethoprimsulfamethoxazole toxicity may have potential benefit.